Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Revenue (2020 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Revenue for 6 consecutive years, with $12.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue rose 78.69% year-over-year to $12.5 million, compared with a TTM value of $38.8 million through Sep 2025, down 21.39%, and an annual FY2024 reading of $47.5 million, up 123.69% over the prior year.
  • Revenue was $12.5 million for Q3 2025 at Fennec Pharmaceuticals, up from $9.7 million in the prior quarter.
  • Across five years, Revenue topped out at $25.4 million in Q1 2024 and bottomed at -$914000.0 in Q4 2022.
  • Average Revenue over 5 years is $6.6 million, with a median of $7.0 million recorded in 2024.
  • The sharpest move saw Revenue surged 2991.38% in 2023, then crashed 65.52% in 2025.
  • Year by year, Revenue stood at $51000.0 in 2021, then crashed by 1892.16% to -$914000.0 in 2022, then skyrocketed by 1165.1% to $9.7 million in 2023, then dropped by 18.59% to $7.9 million in 2024, then skyrocketed by 57.25% to $12.5 million in 2025.
  • Business Quant data shows Revenue for FENC at $12.5 million in Q3 2025, $9.7 million in Q2 2025, and $8.8 million in Q1 2025.